FDA finalizes a 15-year-old sameness map for orphan MAbs
By Mari Serebrov
Tuesday, April 22, 2014
Drugmakers hoping to compete with a monoclonal antibody (MAb) granted a seven-year orphan drug exclusivity have final guidance on what they need to do to differentiate their MAbs to get around the exclusivity.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.